ContributorsPublishersAdvertisers

#Lexx

tekdeeps.com

Arma 3: Western Sahara – Review of a new extension of the Czech military simulator

The Czech shooter Arma 3 is still thriving, thanks to the two-year-old Creators DLC program (abbreviated to “cDLC”), thanks to which creators of modifications in cooperation with the Bohemia Interactive studio can produce additions at a premium level. After the lack of Global Mobilization, the successful SOG from Vietnam and the Czechoslovak Iron Curtain, this time in Western Sahara we will look to Africa.
VIDEO GAMES
Picture for Arma 3: Western Sahara – Review of a new extension of the Czech military simulator

Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study

Lexaria Bioscience Corp. (NASDAQ:LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over the course of two hours.
ECONOMY
Picture for Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
mmjreporter.com

Lexaria Bioscience Corp (NASDAQ: LEXX) Planning for New DehydraTECH Programs in 2022 and Expands Hypertension Program

Lexaria Bioscience Corp (NASDAQ: LEXX) has unveiled plans of various ongoing, and new DehydraTECH applied research and development programs for 2022. Lexaria to conduct a series of DehydraTECH studies in 2022. CEO Chris Bunks said, “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart...
MEDICAL & BIOTECH
Picture for Lexaria Bioscience Corp (NASDAQ: LEXX) Planning for New DehydraTECH Programs in 2022 and Expands Hypertension Program
TRENDING TOPICS
cbdwire.com

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study

Company: Lexaria Bioscience Corp. (LEXX) Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over the course of two hours. “The results from the study showed that the generic nicotine benzoate pouch required about 45 minutes to reach its peak delivery rate. In comparison, the DehydraTECH-nicotine benzoate pouch reached peak delivery rates at both eight minutes and again at 30 minutes. It was further noted that in just four minutes after the pouch was placed in the mouth, the DehydraTECH-nicotine had reached a higher delivery level than the generic achieved at any point during the study,” reads a recent article. Lexaria CEO Chris Bunka commented: “Our technology was ten to twenty times faster in delivering comparable levels of nicotine into bloodstream than the peak of the concentration-matched controls and went on to far exceed their total delivery, which should provide much greater consumer satisfaction.”
MEDICAL & BIOTECH
missionir.com

Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications

Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension. HYPER-H21-4 will build on successes witnessed in initial human hypertension studies. The company, which has a fully funded R&D budget, recently announced new...
MEDICAL & BIOTECH
Benzinga

Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs

Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions. The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets. The 2022 program will continue to focus on the...
MEDICAL & BIOTECH
cbdwire.com

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes

Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions. The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets. The 2022 program will continue to focus on the...
MEDICAL & BIOTECH
mmjreporter.com

Lexaria Bioscience Corp (NASDAQ: LEXX) Commences Study Comparing Its DehydraTECH-CBD With Epidiolex in Paediatric Seizures Treatment

Lexaria Bioscience Corp (NASDAQ: LEXX) has starter a crucial study evaluating evidence of DehydraTECH-CBD’s superior ability to suppress seizures relative to generic cannabidiol and Epidiolex. Epidiolex is currently the only and first FDA-approved CBD drug for seizures treatment related to two severe and rare pediatric epilepsy forms, Dravet syndrome and...
MEDICAL & BIOTECH
scifitalk.com

Byte Rembering With Ellen Dubin

Talented actor and remember her former publicist the late Bill Wanstrom who passed more than a few years ago and we look back on her days on Lexx. A deeply personal episode for me.
CELEBRITIES
YOU MAY ALSO LIKE